摘要
目的研究两种方案治疗类风湿性关节炎(RA)的经济效果和安全性。方法选择病情处于活动期的RA患者120例,随机分为来氟米特组和美洛昔康组,每组60例。基础用药与检查各组均相同。运用药物经济学的成本-效果分析方法对各组进行评价。结果两组方案治疗RA的成本平均每例分别为:来氟米特组(3007.49±590.12)元,美洛昔康组(2656.34±542.56)元;有效率依次为88.3%、80.0%;每获得一个单位效果,依次需花费成本34.06元、33.20元;不良反应的发生率依次为:5.0%、13.3%。结论美洛昔康组成本较低,但有效率较低,不良反应较多;来氟米特组虽成本较高,但有效率较高,不良反应较少。RA患者选用来氟米特组为宜。
OBJECTIVE To investigate the economic effect and safety of two schemes in treatment of rheumatoid arthritis（RA）.METHODS One hundred and twenty patients with RA at active stage were randomly divided into leflunomide group and meloxicam group,each group was 60 cases.The basic medication and examination of these two groups were same.The obtained data were evaluated by the pharmacoeconomic cost-effectiveness analysis.RESULTS The average costs of each patient in leflunomide group and meloxicam group were 2899.49±590.12,2606.34±542.56 yuans,respectives.The effective rates of two groups were 88.3% and 81.7% respectively.The cost of two therapeutic regimen of leflunomide group and meloxicam group were 32.83 and 31.90 yuans,respectively for increasing 1% of effective rate.The incidence rate of adverse reaction in leflunomide group and meloxicam group were 5.0% and 13.3%,respectively.CONCLUSION Between these two groups,the cost of meloxicam group was lower,but the effective was lower and the incidence rate of adverse reaction was higher.The cost of leflunomide group was higher,but the effective was higher and the incidence rate of adverse reaction was lower.So that,leflunomide group was a best group for common patients of RA.
出处
《海峡药学》
2010年第9期194-196,共3页
Strait Pharmaceutical Journal
